IBX
Director Trades
| Date | Director | Value |
|---|---|---|
| R. Proulx | $25,000 | |
| B. Mitchell | $75,000 | |
| Dr Nina Webster | $20,303 |
Company News
Imagion Biosystems Considers Lower Dosage Of Magsense Breast Cancer Imaging Agent For Phase 2 Trial
Imagion Biosystems (ASX: IBX) has received positive results on dosage tests in preparation for a Phase 2 clinical trial of HER2 breast cancer imaging agent MagSense.
Imagion Biosystems Starts Manufacture of MagSense Imaging Agent for Phase 2 HER2 Breast Cancer Trial
Imagion Biosystems (ASX: IBX) has commenced manufacturing of its MagSense imaging agent ahead of a Phase 2 HER2 breast cancer clinical trial to start in the US before year end. The agent will assess axillary nodal disease in patients diagnosed with HER2+ breast cancer and Imagion believes it will be of significant clinical value to […]
Imagion Biosystems Gains FDA Fast-Track Approval for MagSense HER2 Breast Cancer Imaging Agent
Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 breast cancer trial this year. The decision follows a meeting with the US Food and Drug Administration where Imagion offered detailed responses on the structure and operation of the planned trial. The agency’s […]
Imagion Biosystems advances MagSense HER2 imaging agent with FDA application
Cancer detection specialist Imagion Biosystems (ASX: IBX) has taken the next step in progressing its MagSense HER2 imaging agent, lodging an application with the US Food and Drug Administration (FDA). The application for initiated manufacturing of MagSense HER2 is an essential requirement for filing an Investigational New Drug (IND) application with the FDA in mid-2025. […]
Imagion Biosystems presents interim data from MagSense study into breast cancer detection
Cancer detection technology developer Imagion Biosystems (ASX: IBX) has reported a maiden set of results relating to exploratory endpoints for its phase 1 MagSense HER2 breast cancer study. The interim data pertains to a cohort of the first six patients participating in the trial. Interim results were presented at the San Antonio Breast Cancer Symposium […]
Diagnostic imaging: which stock will become the next Pro Medicus?
For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s because they are cheap and convenient. The underlying tech hasn’t really moved on since 1895, when […]
Imagion Biosystems’ nanoparticles could enhance MRI images and reduce costs
Research by the University of Sydney has demonstrated that iron oxide nanoparticles developed by Imagion Biosystems (ASX: IBX) can enable low-field magnetic resonance imaging and could potentially reduce the costs and accessibility of MRI procedures. The report shows how a fundamental challenge which has hampered the development of ultra-low field MRI could be overcome through […]
Imagion Biosystems signs Siemens deal to advance cancer detection technology in MRIs for breast cancer patients
Cancer detection company Imagion Biosystems (ASX: IBX) has signed a collaboration agreement with global medical technology firm Siemens Healthineers to explore the use of Imagion’s MagSense nanoparticles as a contrast agent in magnetic resonance imaging (MRI) procedures for patients with HER2 metastatic breast cancer. The deal will allow Siemens to work with Imagion on the identification of […]
Imagion Biosystems receives FDA breakthrough designation for breast cancer detection device
Imagion Biosystems (ASX: IBX) has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer had qualified for and been granted designation as a “breakthrough device”. Imagion’s MagSense test for the staging of HER2 breast cancer […]
Imagion Biosystems enters clinical development stage of HER2 breast cancer detection reagent; in vivo study in 2019
Cancer detection innovator Imagion Biosystems (ASX: IBX) has announced it will proceed to clinical development of a nanoparticle test reagent designed to enable early identification of HER2 cells in the lymph nodes of breast cancer patients. The company said it had successfully optimised the formulation and its manufacturing partner would begin production of the first […]
Company Videos
No videos found.